Label-free plasma proteomics for the identification of the putative biomarkers of oral squamous cell carcinoma

Gautam, Shashyendra Singh; Singh, R. P.; Karsauliya, Kajal; Sonker, Ashish Kumar; Reddy, Panga Jaipal; Mehrotra, Divya; Gupta, Sudeep; Singh, Sudhir; Singh, Sheelendra Pratap

doi:10.1016/j.jprot.2022.104541

Cited by 10 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The label-free quantitative method has been applied in proteomic profiling of different biological processes, diagnosing cancer biomarkers, and studying proteoform interaction networks [ 255 , 256 , 257 , 258 , 259 ].…”

Section: Advances In Proteomic Technologies Used In the Study Of Cancermentioning

confidence: 99%

Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice

Punetha

Kotiya

2023

Proteomes

View full text Add to dashboard Cite

Proteomics continues to forge significant strides in the discovery of essential biological processes, uncovering valuable information on the identity, global protein abundance, protein modifications, proteoform levels, and signal transduction pathways. Cancer is a complicated and heterogeneous disease, and the onset and progression involve multiple dysregulated proteoforms and their downstream signaling pathways. These are modulated by various factors such as molecular, genetic, tissue, cellular, ethnic/racial, socioeconomic status, environmental, and demographic differences that vary with time. The knowledge of cancer has improved the treatment and clinical management; however, the survival rates have not increased significantly, and cancer remains a major cause of mortality. Oncoproteomics studies help to develop and validate proteomics technologies for routine application in clinical laboratories for (1) diagnostic and prognostic categorization of cancer, (2) real-time monitoring of treatment, (3) assessing drug efficacy and toxicity, (4) therapeutic modulations based on the changes with prognosis and drug resistance, and (5) personalized medication. Investigation of tumor-specific proteomic profiles in conjunction with healthy controls provides crucial information in mechanistic studies on tumorigenesis, metastasis, and drug resistance. This review provides an overview of proteomics technologies that assist the discovery of novel drug targets, biomarkers for early detection, surveillance, prognosis, drug monitoring, and tailoring therapy to the cancer patient. The information gained from such technologies has drastically improved cancer research. We further provide exemplars from recent oncoproteomics applications in the discovery of biomarkers in various cancers, drug discovery, and clinical treatment. Overall, the future of oncoproteomics holds enormous potential for translating technologies from the bench to the bedside.

show abstract

Section: Advances In Proteomic Technologies Used In the Study Of Cancermentioning

confidence: 99%

Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice

Punetha

Kotiya

2023

Proteomes

View full text Add to dashboard Cite

show abstract

“…It is the deadliest tumor in the head and neck (Bugshan & Farooq, 2020), with a high incidence, easy metastasis, poor prognosis, and a 5-year survival rate of only 50-60% (He et al, 2021). Gautam et al (2022) conducted a proteomics analysis of plasma collected from Indian patients with OSCC using the LFQ proteomics approach. They analyzed the data using three software, namely Proteome Discoverer, Trans-Proteomic Pipeline, and MaxQuant, and found that CA1, CRP, and FN1 may act as diagnostic markers for this carcinoma.…”

Section: Oral Squamous Cell Carcinomamentioning

confidence: 99%

Advances in the application of label‐free quantitative proteomics techniques in malignancy research

Meng

Liu

Guan

2023

Biomedical Chromatography

View full text Add to dashboard Cite

Proteomics is the scientific discipline that deals with the protein composition of cells, tissues, and organisms and their patterns of change. It is considered an invaluable tool for tackling many challenges faced in medicine and biology. Among the available approaches, label‐free quantitative proteomics techniques are extensively used to study malignant tumors due to their low cost, simple operation, and short cycle time. Therefore, it provides a novel approach to explore the pathogenesis, diagnostic markers, and targeted drugs of malignant tumors. Here, we summarize the research progress and potential of label‐free quantitative proteomics and discuss the application of such techniques in the research on malignancies.

show abstract

“…Among the markers examined in the aforementioned studies are the basic helix-loop-helix twist homolog (TWIST) transcription factors, the Ki67 cell proliferation marker, the Bcl-2 survival factor, the pro-apoptotic Bax, the protein kinase B (AKT), the pro-invasive matrix metalloproteinases (MMPs), the cell membrane cadherins and connexins, and cytoskeleton components such as keratins or vimentin [ 13 , 14 , 15 , 16 , 17 ]. Further work has focused on the modulators of biological processes that are altered during oral carcinogenesis, such as the remodeling of the extracellular matrix (ECM) [ 18 , 19 , 20 , 21 , 22 ], the metabolism of glucose [ 23 ], and the inflammatory response [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview

Barillari

Melaiu

Gargari

et al. 2022

IJMS

View full text Add to dashboard Cite

Cluster of differentiation (CD)147, also termed extracellular matrix metalloprotease inducer or basigin, is a glycoprotein ubiquitously expressed throughout the human body, the oral cavity included. CD147 actively participates in physiological tissue development or growth and has important roles in reactive processes such as inflammation, immunity, and tissue repair. It is worth noting that deregulated expression and/or activity of CD147 is observed in chronic inflammatory or degenerative diseases, as well as in neoplasms. Among the latter, oral squamous cell carcinoma (OSCC) is characterized by an upregulation of CD147 in both the neoplastic and normal cells constituting the tumor mass. Most interestingly, the expression and/or activity of CD147 gradually increase as healthy oral mucosa becomes inflamed; hyperplastic/dysplastic lesions are then set on, and, eventually, OSCC develops. Based on these findings, here we summarize published studies which evaluate whether CD147 could be employed as a marker to monitor OSCC development and progression. Moreover, we describe CD147-promoted cellular and molecular events which are relevant to oral carcinogenesis, with the aim to provide useful information for assessing whether CD147 may be the target of novel therapeutic approaches directed against OSCC.

show abstract

Label-free plasma proteomics for the identification of the putative biomarkers of oral squamous cell carcinoma

Cited by 10 publications

References 29 publications

Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice

Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice

Advances in the application of label‐free quantitative proteomics techniques in malignancy research

The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview

Contact Info

Product

Resources

About